Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, B-Cell 1Hematologic Neoplasms 1

Interventions

Rituximab 18Cyclophosphamide 17Prednisone 12Doxorubicin 12Vincristine 9Lenalidomide 7ibrutinib 6obinutuzumab 5glofitamab 5Magnetic Resonance Spectroscopy 5polatuzumab vedotin 4fludarabine 4Prednisolone 4Oxaliplatin 4Gemcitabine 4Etoposide 4venetoclax 3pembrolizumab 3fludarabine phosphate 3Whole-Body Irradiation 3Specimen Handling 3R-CHOP protocol 3Cyclosporine 3Biopsy 3zanubrutinib 2prednylidene 2deltacortene 2acalabrutinib 2Mycophenolic Acid 2Ifosfamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × ARQ531 × 30 days × Clear all
NCT06863402 2026-05-20

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Roswell Park Cancer Institute

Phase 2 Recruiting
32 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡